pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,887 catalysts · 4,686 phase readout · 2,347 8k filing · 285 earnings · 201 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: grant×type: phase readout×type: pdufa×clear all
type
  • phase readout4,686
  • 8k filing2,347
  • earnings285
  • pdufa201
  • phase 2 completion172
  • phase 1 completion73
phase 2 initiation
62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area
    • Dermatology1
    • Infectious Disease1

    Date TBD

    50
    ›RECRUITINGphase readoutNCT05159349: Mental Health During the Whole Life Cycle of Community Patients With Schizophrenia

    Sponsor: Shanghai Mental Health Center. Phase: . Conditions: Schizophrenia

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07501338: Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D

    Sponsor: Stanford University. Phase: NA. Conditions: Type 1 Diabetes

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04158258: A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

    Sponsor: Hoffmann-La Roche. Phase: . Conditions: Breast Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04806958: The PulsePoint Study

    Sponsor: Dr. Steven Brooks. Phase: NA. Conditions: Out-Of-Hospital Cardiac Arrest, Heart Arrest, Heart Diseases, Cardiovascular Diseases

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06234748: Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

    Sponsor: University of Michigan Rogel Cancer Center. Phase: PHASE2. Conditions: Oropharynx Cancer, HPV-Related Carcinoma

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04391049: Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

    Sponsor: NRG Oncology. Phase: PHASE1. Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma, Squamous Cell Cancer

    ›RECRUITINGphase readoutNCT06557148: A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

    Sponsor: Memorial Sloan Kettering Cancer Center. Phase: . Conditions: Breast Cancer, Lobular Breast Carcinoma, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Lobular Breast Carcinoma, Metastatic Breast Carcinoma

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06897748: A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils

    Sponsor: AstraZeneca. Phase: PHASE2. Conditions: Chronic Obstructive Pulmonary Disease (COPD)

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05856448: A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

    Sponsor: Lakefront Biotherapeutics NV. Phase: PHASE2. Conditions: Systemic Lupus Erythematosus

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04401748: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

    Sponsor: AbbVie. Phase: PHASE3. Conditions: Myelodysplastic Syndrome (MDS)

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07347548: A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants

    Sponsor: Grünenthal GmbH. Phase: PHASE1. Conditions: Duchenne Muscular Dystrophy (DMD)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05791448: AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

    Sponsor: University of Southern California. Phase: PHASE1. Conditions: Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07518043: A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

    Sponsor: Shanghai Henlius Biotech. Phase: PHASE1. Conditions: Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07264426: Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

    Sponsor: argenx. Phase: . Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07501143: Effects of Physical Training in Patients With Advanced Heart Failure

    Sponsor: University of Nove de Julho. Phase: NA. Conditions: Insuficiência Cardíaca, Transplante Cardíaco, Exercício Físico

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04722835: Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

    Sponsor: University of California, San Francisco. Phase: . Conditions: Copd, Smoking, Tobacco Use

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04738708: Telegenetics or In-Person Genetic Counselling

    Sponsor: National Cancer Centre, Singapore. Phase: . Conditions: Genetic Counselling

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05458908: ProSPective Evaluation of Non-contrast sINe spiN Flat-dEtectoR CT for the Detection of Intracranial hemorrhageS

    Sponsor: University Hospital, Basel, Switzerland. Phase: NA. Conditions: Stroke

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07526376: Unstable Core Training in Air Pistol Athletes

    Sponsor: Shanghai University of Sport. Phase: NA. Conditions: Postural Stability, Motor Control, Sports Performance

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07380776: Preoperative Education Program on Gastrointestinal Quality of Life in Cholecystectomy Patients

    Sponsor: Hawler Medical University. Phase: NA. Conditions: Preoperative Patient Education , Quality of Life , Cholecystectomy

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06683040: Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension

    Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. Phase: PHASE2. Conditions: Pulmonary Arterial Hypertension

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06601140: Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode

    Sponsor: Emobot. Phase: NA. Conditions: Major Depressive Disorder (MDD)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07011940: Walk With Me (WWM) for Perinatal Grief

    Sponsor: Oregon Research Behavioral Intervention Strategies, Inc.. Phase: NA. Conditions: Grief, Post Traumatic Stress Disorder, Suicidal Ideation, Miscarriage, Stillbirth, Infant Death

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07509268: Assessment of the Clinical, Cellular and Molecular Effects of Royalactin-Royal Jelly on the Healing of Wagner Grad II Diabetic Foot Ulcers.

    Sponsor: Universidad Autonoma de Nuevo Leon. Phase: PHASE2. Conditions: Diabetic Foot Ulcer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07446491: A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

    Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.. Phase: PHASE1. Conditions: Thrombocytopenia Associated With Chronic Liver Disease

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07452497: Investigation of the Effect of Kinesiotape Application to the Surgical Area on Pain, Mobilization, Sleep, and Patient Satisfaction

    Sponsor: Busra Ercan. Phase: NA. Conditions: Intraoperative Complications

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05431010: Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia

    Sponsor: The Third Affiliated hospital of Zhejiang Chinese Medical University. Phase: NA. Conditions: Sarcopenia

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT01798810: Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery

    Sponsor: Major Extremity Trauma Research Consortium. Phase: NA. Conditions: Post Operative Surgical Site Infection

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06843720: Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems

    Sponsor: M.D. Anderson Cancer Center. Phase: NA. Conditions: HR-HPV Testing

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05006482: Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

    Sponsor: University of Rochester. Phase: PHASE3. Conditions: Lymphoma, Malignant Solid Neoplasm

    full page →ctgov ↗
    ›WITHDRAWNphase readoutNCT01536782: Optimal Tube Feeding Method in Head and Neck Cancer Patients

    Sponsor: Baylor Research Institute. Phase: NA. Conditions: Head and Neck Cancer

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT05389982: Mobile Health Platform for Surveillance of Kidney Stone

    Sponsor: Northwestern University. Phase: NA. Conditions: Stone, Kidney

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06426823: The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes

    Sponsor: University of Copenhagen. Phase: NA. Conditions: Blood Flow

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05126823: Efficacy of a Combined ACT+ App Intervention to Improve Psychological Flexibility and Associated Symptoms in Cancer Patients

    Sponsor: Francisco Garcia Torres. Phase: NA. Conditions: Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06980259: Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma

    Sponsor: Shandong Cancer Hospital and Institute. Phase: NA. Conditions: Soft Tissue Sarcoma (STS)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06724159: Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

    Sponsor: Spanish Oncology Genito-Urinary Group. Phase: . Conditions: Genitourinary Cancers

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06645080: Vision Screening in Hospitals for Older Adults Following a Fall

    Sponsor: University of Nottingham. Phase: . Conditions: Falls, Vision; Disorder, Loss

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06256146: Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety

    Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre. Phase: NA. Conditions: Peanut Allergy, Milk Allergy, Cow's, Egg Allergy

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06830746: ASCEND CSP IDE Study

    Sponsor: Abbott Medical Devices. Phase: NA. Conditions: Heart Failure, Ventricular Arrythmia

    full page →ctgov ↗
    ›WITHHELDphase readoutNCT07223788: [Trial of device that is not approved or cleared by the U.S. FDA]

    Sponsor: [Redacted]. Phase: . Conditions:

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06941727: Relationship Between Mouth Opening and Masseter Elasticity in Oral Cancer

    Sponsor: National Taiwan University Hospital. Phase: . Conditions: Oral Cancer

    full page →ctgov ↗
    ›WITHDRAWNphase readoutNCT07550361: Validation of Non-Invasive Intracranial Pressure Estimation Using CPMX3 in the Periorbital Vein: A Feasibility Study in Pediatric Patients

    Sponsor: Compremium AG. Phase: NA. Conditions: Intracranial Pressure

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04739761: A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

    Sponsor: AstraZeneca. Phase: PHASE3. Conditions: Breast Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04004442: Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

    Sponsor: University of Oklahoma. Phase: PHASE1. Conditions: Urothelial Carcinoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06441942: Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) of Women With Acute Coronary Syndrome

    Sponsor: IRCCS San Raffaele. Phase: . Conditions: Acute Coronary Syndrome, Gender, Genetic Predisposition

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05703386: Imaging the Pathogenesis of Cerebral Small Vessel Disease

    Sponsor: Johns Hopkins University. Phase: . Conditions: Ischemic Stroke, Hypertension, Hyperlipidemias, Diabetes

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05832086: Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

    Sponsor: Stephen Freedland. Phase: PHASE2. Conditions: Prostate Adenocarcinoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07540286: A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism

    Sponsor: Peking Union Medical College Hospital. Phase: PHASE2. Conditions: Hypoparathyroidism

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07312786: Testing the Feasibility of a Virtual Application to Support Breast and Colorectal Cancer Survivors

    Sponsor: Nova Scotia Health Authority. Phase: NA. Conditions: Breast Cancer Survivor, Colorectal Cancer Survivors

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05760885: Multisensory Augmentation for Post-stroke Standing Balance

    Sponsor: VA Office of Research and Development. Phase: EARLY_PHASE1. Conditions: Stroke

    full page →ctgov ↗
    ← prev
    page 57 of 98
    next →
    full page →ctgov ↗